Logo image of NA

NANO LABS LTD-CL A (NA) Stock Fundamental Analysis

NASDAQ:NA - Nasdaq - KYG6391Y1281 - Common Stock - Currency: USD

4.86  +0.08 (+1.67%)

Fundamental Rating

0

Overall NA gets a fundamental rating of 0 out of 10. We evaluated NA against 110 industry peers in the Semiconductors & Semiconductor Equipment industry. NA has a bad profitability rating. Also its financial health evaluation is rather negative. NA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NA had negative earnings in the past year.
NA Yearly Net Income VS EBIT VS OCF VS FCFNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -100M -200M -300M

1.2 Ratios

NA has a worse Return On Assets (-85.20%) than 95.41% of its industry peers.
The Return On Equity of NA (-789.98%) is worse than 95.41% of its industry peers.
Industry RankSector Rank
ROA -85.2%
ROE -789.98%
ROIC N/A
ROA(3y)-27.64%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NA Yearly ROA, ROE, ROICNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 500 1K 1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NA Yearly Profit, Operating, Gross MarginsNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

0

2. Health

2.1 Basic Checks

NA does not have a ROIC to compare to the WACC, probably because it is not profitable.
NA has less shares outstanding than it did 1 year ago.
The debt/assets ratio for NA is higher compared to a year ago.
NA Yearly Shares OutstandingNA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 20M 40M 60M
NA Yearly Total Debt VS Total AssetsNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

NA has an Altman-Z score of 0.72. This is a bad value and indicates that NA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NA (0.72) is worse than 73.39% of its industry peers.
NA has a Debt/Equity ratio of 2.05. This is a high value indicating a heavy dependency on external financing.
NA's Debt to Equity ratio of 2.05 is on the low side compared to the rest of the industry. NA is outperformed by 93.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.05
Debt/FCF N/A
Altman-Z 0.72
ROIC/WACCN/A
WACC8.1%
NA Yearly LT Debt VS Equity VS FCFNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 100M -100M -200M -300M

2.3 Liquidity

A Current Ratio of 0.70 indicates that NA may have some problems paying its short term obligations.
NA has a worse Current ratio (0.70) than 95.41% of its industry peers.
A Quick Ratio of 0.49 indicates that NA may have some problems paying its short term obligations.
NA has a Quick ratio of 0.49. This is amonst the worse of the industry: NA underperforms 93.58% of its industry peers.
Industry RankSector Rank
Current Ratio 0.7
Quick Ratio 0.49
NA Yearly Current Assets VS Current LiabilitesNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 200M 400M 600M 800M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for NA have decreased strongly by -1579.31% in the last year.
The Revenue for NA has decreased by -92.03% in the past year. This is quite bad
The Revenue has been growing by 232.71% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1579.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.07%
Revenue 1Y (TTM)-92.03%
Revenue growth 3Y232.71%
Revenue growth 5YN/A
Sales Q2Q%-86.25%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NA Yearly Revenue VS EstimatesNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 200M 400M 600M 800M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NA Price Earnings VS Forward Price EarningsNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NA Per share dataNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NANO LABS LTD-CL A

NASDAQ:NA (5/2/2025, 8:11:50 PM)

4.86

+0.08 (+1.67%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)03-25 2025-03-25/bmo
Earnings (Next)09-16 2025-09-16
Inst Owners0.05%
Inst Owner Change-62.72%
Ins Owners5.07%
Ins Owner Change0.01%
Market Cap317.49M
AnalystsN/A
Price TargetN/A
Short Float %1.81%
Short Ratio8.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.45
P/FCF N/A
P/OCF N/A
P/B 72.08
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.95
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.17
BVpS0.07
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -85.2%
ROE -789.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.64%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 2.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.7
Quick Ratio 0.49
Altman-Z 0.72
F-ScoreN/A
WACC8.1%
ROIC/WACCN/A
Cap/Depr(3y)1473.05%
Cap/Depr(5y)N/A
Cap/Sales(3y)54.5%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1579.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.07%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-92.03%
Revenue growth 3Y232.71%
Revenue growth 5YN/A
Sales Q2Q%-86.25%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1360.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.45%
OCF growth 3YN/A
OCF growth 5YN/A